RecruitingNCT06229210
26-week safety study of lumateperone in children and adolescents
About this title
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Read the official source — NCT06229210Medication studyAges 5–17Multiple countriesBipolarity
Understand this study
Who could participate?
Listed age limits: 5 years to 17 years.
- Listed locations
- Phoenix and 64 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 25, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 300
- Sponsor
- Intra-Cellular Therapies, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Colombia, Serbia
- Age range
- From 5 Years to 17 Years
- Official registry ID
- NCT06229210
- Official title
Show the full official title
An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone in the Treatment of Pediatric Patients With Schizophrenia, Bipolar Disorder, or Autism Spectrum Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Phoenix, United States · Little Rock, United States · Anaheim, United States
48 more locations
- Garden Grove, United States
- Oceanside, United States
- Redlands, United States
- Sacramento, United States
- San Diego, United States
- West Covina, United States
- Colorado Springs, United States
- Fort Myers, United States
- Gainesville, United States
- Hialeah, United States
- Homestead, United States
- Jacksonville, United States
- Miami, United States
- Miami Gardens, United States
- Miami Lakes, United States
- Orlando, United States
- Pompano Beach, United States
- St. Petersburg, United States
- West Palm Beach, United States
- Atlanta, United States
- Lawrenceville, United States
- Savannah, United States
- Naperville, United States
- Indianapolis, United States
- Bloomfield Hills, United States
- Saint Charles, United States
- Lincoln, United States
- Las Vegas, United States
- New York, United States
- Staten Island, United States
- Avon Lake, United States
- Cincinnati, United States
- Garfield Heights, United States
- Norman, United States
- Oklahoma City, United States
- Nashville, United States
- Coppell, United States
- Fort Worth, United States
- Houston, United States
- Plano, United States
- Richmond, United States
- Bellevue, United States
- Everett, United States
- Barranquilla, Colombia
- Bello, Colombia
- Belgrade, Serbia
- Niš, Serbia
- Novi Sad, Serbia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Intra-Cellular Therapies, Inc.
Does this study involve medication?
Yes. The study involves medication, including Lumateperone.
Who can participate?
Listed age limits: 5 years to 17 years.
Is this study still recruiting?
The registry lists this study as recruiting.
